Frances Oldham Kelsey papers, 1890-2016 (Library of Congress Finding Aid)

Access restrictions apply.Some or all content stored offsite.

Container	Contents

	Part II: Subject File, 1902-2012 (continued)
BOX II:130				General
BOX II:130					1963-1981
BOX II:130						(3 folders)
BOX II:131					1982-1997, undated
BOX II:131						(5 folders)
BOX II:131				Warning letters to investigators, circa 1993-1998
BOX II:131			Institutional Review Branch
BOX II:131				1972-1979
BOX II:131				1980
BOX II:131					(1 folder)
BOX II:132					(2 folders)
BOX II:132				1981
BOX II:132					(3 folders)
BOX II:132				1982
BOX II:132					(1 folder)
BOX II:133					(3 folders)
BOX II:133				1983-1984, 1991, 1999, undated
BOX II:133					(3 folders)
BOX II:133			Nonclinical Laboratory Studies Branch
BOX II:133				Good laboratory practices See Containers II:147-II:148, same heading
BOX II:133				Significant investigations prior to June 20, 1979 (Government Accounting Office request), 1987
BOX II:133			Methadone Monitoring Branch See Container II:172, Methadone monitoring
BOX II:133			Paperwork systems and procedures, 1976-1978, 1999
BOX II:134			Policies and procedures, 1973-1990, undated
BOX II:134				(2 folders)
BOX II:134			Radioactive Drug Research Committees, 1974-1984, 1992, 1999, undated
BOX II:134				(2 folders)
BOX II:134			Regulatory Management Branch, 1977-1991, 1999, undated
BOX II:134				(3 folders)
BOX II:134			Speeches by division members
BOX II:134				1967, 1971-1972
BOX II:135				1980-1992, undated
BOX II:135					(5 folders)
BOX II:135		DMSO (Drug)
BOX II:135			1963-1966
BOX II:135				(2 folders)
BOX II:136			1980-1983, 1994-1999, undated
BOX II:136				(3 folders)
BOX II:136		Doriden, 1962-1972, 1995, undated
BOX II:136		Dornwal, 1964, 1997, undated
BOX II:136		Drobuline, 1982-1983, 1997 See also Container II:139, Eli Lilly and Co. Task Group
BOX II:136		Drug controls, foreign
BOX II:136			1958-1987
BOX II:136				(5 folders)
BOX II:137			1988-1993, undated
BOX II:137				(8 folders)
BOX II:138		Drug equivalency, 1966-1971, 1982-1990, undated
BOX II:138		Drug Research Board, National Academy of Sciences, 1965-1973, 1996
BOX II:138			(2 folders)
BOX II:138		Drugs and deformities
BOX II:138			1960-1987
BOX II:138				(4 folders)
BOX II:139			1990-2000, undated
BOX II:139		Dusheiko, Geoffrey M., 1994-1996
BOX II:139		Edgewood Arsenal, Edgewood, Md., site visit, 1965, 1972-1975, 1997
BOX II:139		Efficacy guidelines See Container II:148, Guidance for Industry: Providing Adequate Clinical Evidence of Effectiveness , draft
BOX II:139		Eflornithine See Container II:128, DFMO (Drug)
BOX II:139		Eli Lilly and Co. Task Group See also Container II:100, Benoxaprofen ; Container II:128, Darvon ; Container II:136, Drobuline
BOX II:139			General, 1980-1981
BOX II:139			Report, 1983
BOX II:139				(2 folders)
BOX II:139		Elixir sulfanilamide, 1967, 1983, circa 1993, 2002
BOX II:139		Ellenhorn, Matthew J., 1963, circa 1966, 1996-1999
BOX II:140		Enzymes, 1960-1962, 1996
BOX II:140		Epidemiology, 1962-1988, undated
BOX II:140			(3 folders)
BOX II:140		Establishment Evaluation System
BOX II:140			Division of Scientific Investigations, flow charts and milestones, circa 1995-circa 1996
BOX II:140			General, 1995-1996
BOX II:140		Ethical consideration
BOX II:140			1965-1979
BOX II:140				(2 folders)
BOX II:141			1980-1999, undated
BOX II:141		Ethical criteria, 1960-2001, undated
BOX II:141			(5 folders)
BOX II:141		European Teratology Society, 1971-1977, 1994-2000
BOX II:141			(2 folders)
BOX II:142		Executive Women in Government, 1994-1996
BOX II:142		Exempt drugs, 1979
BOX II:142		FDA Distinguished Alumni/Professor Emeritus Policy Task Force, 1998
BOX II:142		Federal Executive Professional Association, 1979-1986, 1998
BOX II:142		Feldene (piroxicam), 1983-1986
BOX II:142		Fetus and newborn, miscellaneous, 1961-1979, 1985-1986, undated
BOX II:142			(2 folders)
BOX II:142		Fialuridine (FIAU), 1993-1994, 2001
BOX II:142		Flunixin, 1976-1977
BOX II:142		Folic acid, memorandum to John Patrick Swann with attachments, 1951-1952, 1963, 1995, undated
BOX II:143		Foreign clinical studies, U.S. Food and Drug Administration policy, 1973-1992, undated
BOX II:143			(3 folders)
BOX II:143		Foreign travel requests, 1978-1982
BOX II:143		Foreign visitors, 1963-1968, 1979-1986, 1994-1997
BOX II:143		Fraud in science, cases and publicity
BOX II:143			circa 1961-1987
BOX II:143				(4 folders)
BOX II:144			1988-1999, undated
BOX II:144				(5 folders)
BOX II:144		Freedom of Information Act, correspondence and requests
BOX II:144			1977-1980
BOX II:145			1981-1987
BOX II:145		G. D. Searle & Co.
BOX II:145			Aldactone, 1975
BOX II:145			Aspartame/NutraSweet, 1983-1996, undated
BOX II:145			Copper-7, 1988, 1997
BOX II:145			Enovid/Ovulen, 1962, 1979
BOX II:145			Searle Investigation Task Force, 1975-1976, 1982-1985
BOX II:145				(2 folders)
BOX II:145		Gene therapy, death in, 1980-1981, 1999-2000
BOX II:145		General Accounting Office
BOX II:145			Anticancer drugs, 1983
BOX II:145			General
BOX II:145				1973-1976
BOX II:146				1986-1990
BOX II:146		Generic drugs, 1987-1989
BOX II:146		Genetic factors, 1956-1990, undated
BOX II:146			(6 folders)
BOX II:146		Gerovital, 1976-1980, 1999
BOX II:146		Gibson, William C., 1957-1963, 1996-2001
BOX II:146		“Ginger jake” affair, 1991-1994
BOX II:147		Good laboratory practices
BOX II:147			1964-1981
BOX II:147				(9 folders)
BOX II:148			1982-1992, 1999, undated
BOX II:148				(5 folders)
BOX II:148		Grecu, Eugen O., informal conference at U.S. Food and Drug Administration, transcript and exhibits, 1992
BOX II:148		Griseofulvin, 1963-1974, 1982-1988, undated
Next Page »

Frances Oldham Kelsey papers, 1890-2016

Contents List